Zanubrutinib,Ibrutinib
beigene,janssen,abbvie
['zanubrutinib', 'cll', ' ibru']
in patients with relapsed or refractory #cll or #sll, progression-free survival was longer among patients who received #zanubrutinib than among those who received #ibrutinib, and zanubrutinib was associated with fewer cardiac adverse events. #ash22 
Non-Profit Founder/Leader | ?? Doc | Artist | Scientist | Educator | News Anchor https://t.co/7OIKCgMVAT | RT ? endorse | Disclaimer: https://t.co/bwmE2O3U5W